[Impact and applicability of the system of reference prices].
作者信息
Segú Tolsà J L, Zara Yahn C
机构信息
CAP Barceloneta, Spain.
出版信息
Aten Primaria. 2001 Sep 30;28(5):340-8. doi: 10.1016/s0212-6567(01)70386-1.
Abstract
摘要
相似文献
1
[Impact and applicability of the system of reference prices].
Aten Primaria. 2001 Sep 30;28(5):340-8. doi: 10.1016/s0212-6567(01)70386-1.
2
[The new reference prices: an opportunity for efficient management of medication].
Aten Primaria. 2005 Feb 15;35(2):64-6. doi: 10.1157/13071910.
3
[Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effects].
Gesundheitswesen. 2005 Jul;67(7):468-77. doi: 10.1055/s-2005-858485.
4
Pharmaceutical reference prices. How do they work in practice?
Pharmacoeconomics. 1998 Nov;14(5):471-9. doi: 10.2165/00019053-199814050-00002.
5
[International reference prices and cost minimization analysis for the regulation of medicine prices in Colombia].
Value Health. 2011 Jul-Aug;14(5 Suppl 1):S16-9. doi: 10.1016/j.jval.2011.05.034.
6
Pharmaceutical price regulation and its impact on drug innovation: mitigating the trade-offs.
Expert Opin Ther Pat. 2021 Mar;31(3):189-192. doi: 10.1080/13543776.2021.1876029. Epub 2021 Feb 10.
7
Adapting pharmacoeconomic data and methods to extend the postpublication utility of analyses.
Clin Ther. 2009 Jan;31(1):192-3. doi: 10.1016/j.clinthera.2009.01.008.
8
Effects of regulation on drug launch and pricing in interdependent markets.
Adv Health Econ Health Serv Res. 2012;23:35-71. doi: 10.1108/s0731-2199(2012)0000023005.
9
Insurance against drug costs--a progress report.
Am J Public Health Nations Health. 1960 May;50(5):670-4. doi: 10.2105/ajph.50.5.670.
10
Grounding Value-Based Drug Pricing in Population Health.
Clin Pharmacol Ther. 2020 Jun;107(6):1290-1292. doi: 10.1002/cpt.1741. Epub 2020 Jan 17.
引用本文的文献
1
[The new reference prices: an opportunity for efficient management of medication].
Aten Primaria. 2005 Feb 15;35(2):64-6. doi: 10.1157/13071910.
本文引用的文献
1
Review of the literature on reference pricing.
Health Policy. 2000 Nov 17;54(2):87-123. doi: 10.1016/s0168-8510(00)00100-7.
2
Evaluating reference-based pricing: initial findings and prospects.
CMAJ. 1999 Aug 10;161(3):286-8.
3
Pharmaceutical reference prices. How do they work in practice?
Pharmacoeconomics. 1998 Nov;14(5):471-9. doi: 10.2165/00019053-199814050-00002.
4
Pricing and reimbursement of pharmaceuticals in Sweden.
Pharmacoeconomics. 1994;6 Suppl 1:51-60. doi: 10.2165/00019053-199400061-00013.
5
General practitioner fundholding and prescribing expenditure control. Evidence from a rural English health authority.
Pharmacoeconomics. 1997 Apr;11(4):350-8. doi: 10.2165/00019053-199711040-00006.
6
Healthcare reform and expenditure on drugs. The German situation.
Pharmacoeconomics. 1996;10 Suppl 2:81-8. doi: 10.2165/00019053-199600102-00013.
7
The 1996 pricing and reimbursement policy in The Netherlands.
Pharmacoeconomics. 1996;10 Suppl 2:75-80. doi: 10.2165/00019053-199600102-00012.
8
Cost sharing for pharmaceuticals--the Swedish reimbursement system.
Pharmacoeconomics. 1996;10 Suppl 2:68-74. doi: 10.2165/00019053-199600102-00011.
9
Consequences of implementing a drug budget for office-based physicians in Germany.
Pharmacoeconomics. 1996;10 Suppl 2:37-47. doi: 10.2165/00019053-199600102-00007.
10
The effect of competition on drug prices.
Pharmacoeconomics. 1995 Dec;8(6):473-8. doi: 10.2165/00019053-199508060-00003.
Zotero 插件